RxDoctor Payments Data

Ronald Levine, MD

Interventional Cardiology · Naples, FLNPI 1558354399

Payments from drug & device makers

$5,400in general payments, 2019–2025

Across 196 payments — averaging $27.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Novartis$514
  • Johnson & Johnson$462
  • Boehringer Ingelheim$377
  • Amgen$345
  • Pfizer$229
  • plus $2K from 28 others

What the payments were for

  • Travel & lodging$96018%
  • Food & beverage$4,44082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,400 in reported general payments places this provider in the 30th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$2,509,427
Medicare patients
1,693
Services billed
20,121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban126$180,104
Repatha SureclickEvolocumab39$38,825
EntrestoSacubitril/Valsartan27$37,966
XareltoRivaroxaban11$18,097
Amlodipine Besylate371$3,711
Metoprolol Succinate226$3,682
Rosuvastatin Calcium242$3,402
Atorvastatin Calcium298$3,141
Losartan Potassium243$2,617
Telmisartan88$2,323
ClopidogrelClopidogrel Bisulfate184$2,086
Doxazosin Mesylate75$2,046
Nebivolol Hcl31$1,818
Isosorbide Mononitrate ErIsosorbide Mononitrate89$1,517
Prasugrel Hcl27$1,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$229$180,104126 claims
NovartisEntresto$514$37,96627 claims
Johnson & JohnsonXarelto$462$18,09711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →